GlassScriptPhysician profile
Anas Abudan
NPI 1265937809
$5,173.21
in general payments reported to CMS, 2019-2025
17 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $2,138 · 2023: $1,513 · 2024: $795 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735 · Travel and Lodging: $574 · Education: $345 · Consulting Fee: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.08 |
| Travel and Lodging | $573.95 |
| Education | $345.35 |
| Consulting Fee | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,845.40 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Abiomed | $1,100.54 | 2021-2023 | Impella |
| Abbott Laboratories | $612.89 | 2023-2024 | Ensite, Ensite Precision, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $452.86 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.31 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $139.00 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $125.00 | 2025 | Winrevair |
| Amgen INC. | $123.89 | 2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $123.89 | 2025 | Opsumit, Uptravi |
| Lantheus Medical Imaging, INC. | $100.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.94 | 2024 | Jardiance |
| Atricure, INC. | $70.19 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $62.07 | 2024 | Xarelto |
| Zoll Circulation INC | $48.27 | 2022 | |
| Sentynl Therapeutics, INC. | $40.00 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $23.87 | 2022 | |
| Novo Nordisk INC | $19.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Abudan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.